Related Experiment Video
Updated: Jan 7, 2026
08:57
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
27.6K
Advances in Therapeutics Research for Demyelinating Diseases
Jinhui Jiang1, Yuchen Sun1, Yuan Ma2
1Zhejiang Key Laboratory of Organ Development and Regeneration, College of Life and Environmental Sciences, Hangzhou Normal University, Hangzhou 311121, China.
Pharmaceuticals (Basel, Switzerland)
|December 31, 2025
Summary
Demyelinating diseases damage myelin, and current treatments only manage relapses. New research focuses on novel drugs and technologies to promote myelin repair and neural reconstruction.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Demyelinating diseases are chronic neurological disorders characterized by myelin sheath destruction.
- Pathogenesis involves immune-mediated damage to oligodendrocytes (Ols), neuroinflammation, and impaired epigenetic repair.
- Current therapies control relapses but fail to promote neural repair.
Purpose of the Study:
- To review emerging therapeutic strategies for demyelinating diseases focusing on neuroprotection and remyelination.
- To explore novel pharmaceuticals and innovative technologies for myelin repair.
- To identify challenges and future directions in drug development for these conditions.
Main Methods:
- Literature review of current and emerging therapeutic approaches for demyelinating diseases.
- Analysis of novel pharmaceuticals targeting oligodendrocyte maturation and epigenetic silencing.
- Evaluation of innovative technologies including cell therapy, gene therapy, and drug delivery systems.
Main Results:
- Novel pharmaceuticals and technologies show promise for remyelination and neural repair.
- Interventions include drugs targeting oligodendrocyte maturation, epigenetic silencing, and signal pathways.
- Innovative technologies encompass cell therapies, gene therapy, and advanced drug delivery systems.
Conclusions:
- Emerging therapies offer new hope for treating demyelinating diseases beyond relapse control.
- Addressing challenges like disease heterogeneity and blood-brain barrier penetration is crucial.
- Future efforts should focus on precision medicine and synergistic therapies for functional neural reconstruction.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
01:29Microorganisms in Medicine and Therapeutics
911
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
911